Phase II feasibility study of concurrent radiotherapy and gemcitabine in chemonaive patients with squamous cell carcinoma of the head and neck: Long-term follow up data

Annals of Oncology

Volumn 18, Issue 11, 2007, Pages 1856-1860

  Specenier, Pol M ^a   Van den Weyngaert, D ^b   Van Laer, C ^a   Weyler, J ^c   Van den Brande, J ^a   Huizing, M T ^a   Dyck, J ^a   Schrijvers, D ^a,b   Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b ZNA Hospitals   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Chemoradiation; Gemcitabine; Head and neck cancer; Squamous cell carcinoma

Indexed keywords

GEMCITABINE;

ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; EAR NOSE THROAT SURGERY; ESOPHAGITIS; FEASIBILITY STUDY; FEEDING APPARATUS; FEMALE; FOLLOW UP; FOOD INTAKE; HEAD AND NECK CARCINOMA; HUMAN; HYPOPHARYNX CARCINOMA; LARYNGECTOMY; LARYNX CARCINOMA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; ORAL MUCOSAL DISEASE; OROPHARYNX CARCINOMA; PARANASAL SINUS CARCINOMA; PHARYNGITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; RADIATION RESPONSE; SKIN FIBROSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; XEROSTOMIA;

EID: 36148966978     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm346     Document Type: Article

References (40)

1. Vokes EE, Weichselbaum RR, Lippman SM et al. Head and neck cancer. N Engl J Med 1993; 328: 184-194.
2. Adelstein DJ, Li Y, Adams GL et al. An Intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21: 92-98.
3. Zorat PL, Paccagnella A, Cavaniglia G et al. Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: A 10-year follow-up. J Natl Cancer Inst 2004; 96: 1714-1717.
4. Vokes E, Kies MS, Haraf DJ et al. Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer. J Clin Oncol 2006; 18: 1652-1661.
5. Calais G, Alfonsi M, Bardet E et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst 1999; 91: 2081-2086.
6. Wendt TG, Grabenbauer GC, Rodel CM et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: A randomized multicenter trial. J Clin Oncol 1998; 16: 1318-1324.
7. Adelstein DJ, Saxton JP, Lavertu P et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and i.v. squamous cell head and neck cancer: Preliminary results. Cancer 1999; 19: 567-575.
8. Brizel DM, Albers ME, Fisher RS et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338: 1798-1804.
9. Pignon JP, Bourhis J, Domenge C et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet 2000; 355: 949-955.
10. Plunkett W, Huang P, Xu Y-Z et al. Gemcitabine: Metabolism, mechanisms of actions, and self-potentiation. Semin Oncol 1995; 22 (Suppl 11): 3-10.
11. Plunkett W, Huang P, Gandhi V. Preclinical characteristics of gemcitabine. Anti-Cancer Drugs 1995; 6 (Suppl 6): 7-13.
12. Hertel LW, Boder GB, Kroin JS et al. Evaluation of anti-trumor activity of 2′,2′- difluoro-2′-deoxycytidine, Cancer Res 1990; 50: 4417-4422.
13. Braakhuis BJ, van Dongen AMS, Vermorken JB et al. Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against head and neck cancer. Cancer Res 1991; 51: 211-214.
14. Guchelaar HJ, Richel DJ, van Knapen A. Clinical toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996; 22: 13-31.
15. Braakhuis BJM, Ruiz van Haperen VWT, Welters MJP et al. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur J Cancer 1995; 31A: 2335-2340.
16. Catimel G, Vermorken JB, Clavel M et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. EORTC Early Clinical Trials Group. Ann Oncol 1994; 5: 543-547.
17. Garcia-Carbonero R, Hitt R, Castellano D et al, Phase II trial of cisplatin (C) and gemcitabine (G) in advanced squamous cell carcinoma of the head and neck (AHNC). Proc Am Soc Clin Oncol 1998; 17: 392a (Abstr 1511).
18. Eisbruch A, Shewach DS, Urba S et al. Phase I trial of radiation concurrent with low-dose gemcitabine for head and neck cancer: High mucosal and pharyngeal toxicity. Proc Am Soc Clin Oncol 1997; 16: 386a (Abstr 1377).
19. Eisbruch A, Shewach DS, Bradford CR et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: A phase I trial and intracellular drug incorporation study. J Clin Oncol 2001; 19: 792-799.
20. Pauwels B, Korst AE, Lardon F et al. Combined modality of gemcitabine and radiation. Oncologist 2005; 10: 34-51.
21. Aguilar-Ponce JL, Granados-Garcia M, Villavicencio V et al. Phase II trial of gemcitabine concurrent with radiation for locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2004; 15: 301-306.
22. Trotti A, Bellm LA, Epstein JB et al. Mucositis incidence, severity and associated outcomes in patents with head and neck cancer receiving radiotherapy with of without chemotherapy: A systematic literature review. Radiother Oncol 2003; 66: 253-262.
23. Bourhis J, Overgaard J, Ang KK et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet 2006; 368: 843-854.
24. Jabbari S, Kim HM, Feng M et al. Matched case-control study of quality of life and xerostomia after intensity-modulated radiotherapy or standard radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2005; 63: 725-731.
25. Fang M, Jabbari S, Lin A et al. Predictive factors of local-regional recurrences following parotid sparing intensity modulated or 3D conformal radiotherapy for head and neck cancer. Radiother Oncol 2005; 77: 32-38.
26. Langendijk JA, de Jong MA, Leemans CR et al. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: The importance of the overall treatment time. Int J Radiat Oncol Biol Phys 2003; 57: 693-700.
27. Suwinski R, Sowa A, Rutkowski T et al. Time factor in postoperative radiotherapy: A multivariate locoregional control analysis in 868 patients. Int J Radiat Oncol Biol Phys 2003; 56: 399-412.
28. Tarnawki R, Fowler J, Skladowskj K et al. How fast is repopulation of tumor cells during the treatment gap? Int J Radiat Oncol Biol Phys 2002; 54: 229-236.
29. Hoffstetter S, Marchal C, Peiffert D et al. Treatment duration as a prognosfic factor for local control and survival in epidermoid carcinoma of the tonsillar region treated by combined external beam irradiation and brachytherapy. Radiother Oncol 1997; 45: 141-148.
30. Nguyen NP, Moitz CC, Frank C et al. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004; 15: 383-388.
31. Shiley SG, Hargunani CA, Skoner JM et al. Swallowing function after chemoradiation for advanced stage oropharyngeal cancer. Otolaryngol Head Surg 2006; 134: 455-459.
32. Goguen LA, Posner MR, Norris CM et al. Dysphagia after sequential chemoradiation therapy for advanced head and neck cancer. Otolaryngol Head Surg 2006; 134: 916-922.
33. Fields MT, Eisbrüch A, Normolle D et al. Radiosensitization produced in vivo by once- vs twice-weekly 2′2′-difluoro-2′deoxycitidine (gemcitabine). Int J Radiat Oncol Biol Phys 2000; 47: 785-791.
34. Blackstock AW, Bernard SA, Richards F et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17: 2208-2212.
35. Blackstock AW, Richards F, White D et al. Twice-weekly gemcitabine and concurrent thoracic iadiation for non small-cell lung cancer. Clin Lung Cancer 1999; 1: 153-154.
36. Jones PD, de Lorimier LP, Kitchell BE et al. Gemcitabine as a radiosensitizer for nonresectable feline oral squamous cell carcinoma. J Am Anim Hosp Assoc 2003; 39: 469-467.
37. Duenas-Gonzales A, Cetina-Perez L, Lopez-Graniel C et al. Pathologic response and toxicity assessment of chemoradiotherapy with cisplatin versus cisplatin plus gemcitabine in cervical cancer: A randomized phase II study. Int J Radiat Oncol Biol Phys 2005; 61: 817-823.
38. Benasso M, Corvo R, Ponzanelli A et al. Alternating cisplatin with gemcitabine and radiation in stage i.v. squamous cell carcinoma of the head and neck. Annal Oncol 2004; 15: 646-652.
39. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578.
40. Chun PY, Feng FY, Schuerer AM et al. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006; 66: 981-988.